gadolinium dtpa has been researched along with niacinamide in 5 studies
| Studies (gadolinium dtpa) | Trials (gadolinium dtpa) | Recent Studies (post-2010) (gadolinium dtpa) | Studies (niacinamide) | Trials (niacinamide) | Recent Studies (post-2010) (niacinamide) |
|---|---|---|---|---|---|
| 12,654 | 664 | 4,051 | 13,381 | 1,097 | 5,797 |
| Protein | Taxonomy | gadolinium dtpa (IC50) | niacinamide (IC50) |
|---|---|---|---|
| Chain A, NAD-dependent deacetylase | Thermotoga maritima | 1000 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 3.3 | |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | 2.9 | |
| NAD-dependent protein deacetylase sirtuin-3, mitochondrial | Homo sapiens (human) | 8.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C | 1 |
| Kudo, M | 1 |
| Akisik, MF; Bu, G; Chiorean, EG; Hutchins, GD; Lin, C; Sandrasegaran, K | 1 |
| Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D | 1 |
| Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S | 1 |
2 trial(s) available for gadolinium dtpa and niacinamide
| Article | Year |
|---|---|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Proportional Hazards Models; Prospective Studies; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2010 |
3 other study(ies) available for gadolinium dtpa and niacinamide
| Article | Year |
|---|---|
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Gadolinium DTPA; Humans; Infusion Pumps; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Protein Precursors; Prothrombin; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate | 2010 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Tumor Burden | 2011 |
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution | 2015 |